TherapeuticsMD (TXMD) Misses Q2 EPS by 17c

TherapeuticsMD (NASDAQ: TXMD) reported Q2 EPS of ($0.24), $0.17 worse than the analyst estimate of ($0.07).

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Amneal gets FDA approval for lanreotide injection, launches immediately
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2